Singapore, Sept. 4 -- Hutchmed (China) has announced that its subsidiary, Hutchmed Limited has entered into an exclusive development and license agreement with a subsidiary of GSK plc, granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830.

Clinical development will initially focus on colorectal, pancreatic and lung cancer indications. The agreement includes a $110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of $1.295 billion, and royalties on net sales.

This first-in-class drug candidate, an Antibody-Targeted Therapy Conjugate (ATTC), comprises a highly selective and potent Kirsten ra...